N Ruperto
Great Ormond Street Hospital
JuvenileInternal medicinePhysical therapyPediatricsRheumatologyImmunologyPlaceboArthritisTocilizumabJuvenile dermatomyositisDiseaseAbataceptCanakinumabAdalimumabMethotrexatePaediatric rheumatologyIn patientDisease activityFamily medicineClinical trialMedicineGastroenterology
132Publications
7H-index
428Citations
Publications 136
Newest
#1Nicolino Ruperto (Istituto Giannina Gaslini)H-Index: 82
#3Alyssa SprolesH-Index: 12
Last. Hermine I. BrunnerH-Index: 57
view all 18 authors...
Source
#1Gabriella GiancaneH-Index: 10
#2Riccardo PapaH-Index: 26
Last. NM WulffraatH-Index: 28
view all 25 authors...
Source
#1Hermine I. Brunner (Cincinnati Children's Hospital Medical Center)H-Index: 57
#2Nikolay TzaribachevH-Index: 22
Last. N RupertoH-Index: 7
view all 19 authors...
Introduction Le maintien de la reponse clinique au cours du temps a ete demontre chez les patients atteints d’une arthrite juvenile idiopathique avec une atteinte polyarticulaire (AJIp) traites par abatacept (ABA) SC. Il n’est pas connu si les patients avec une efficacite maintenue du traitement presentent egalement un maintien des reponses rapportees par les patients (PROs). L’objectif est donc d’examiner si l’efficacite au traitement par ABA, combinee aux reponses PROs optimales, sont maintenu...
Source
#1Romina GallizziH-Index: 20
#2Marta BustaffaH-Index: 1
Last. M GattornoH-Index: 4
view all 18 authors...
Background: Colchicine is the standard treatment for Familiar Mediterranean Fever (FMF), however about 5% of patients experience colchicine resistance. There is no standard definition of colchicine resistance. Recently a panel of experts elaborated a new definition based on a Delphi consensus approach. Objectives: We aim to describe main features of the disease and clinical outcome of a cohort of FMF patients with particular interest on the colchicine resistance and tolerability according to the...
1 CitationsSource
#1Hermine I. Brunner (Cincinnati Children's Hospital Medical Center)H-Index: 57
#2Nikolay TzaribachevH-Index: 22
Last. N RupertoH-Index: 7
view all 18 authors...
Background: Maintenance of clinical response over time has been shown in individual patients (pts) with polyarticular-course juvenile idiopathic arthritis (pJIA) treated with SC abatacept (ABA).1 It is unknown whether each individual pt with sustained efficacy also consistently maintains the previously reported shorter-term benefits on patient-reported outcomes (PROs)2,3 over time. Objectives: Investigate whether combined efficacy and stringent, optimal PRO responses to ABA treatment are maintai...
Source
#1I GueliH-Index: 2
#2Martina FinettiH-Index: 13
Last. Marco GattornoH-Index: 75
view all 18 authors...
#1N RupertoH-Index: 7
#2Hermine I. BrunnerH-Index: 57
Last. Daniel J. LovellH-Index: 57
view all 19 authors...
Background Infections are the most common expected AEs linked to biologic (b) DMARDs in paediatric patients (pts) with juvenile idiopathic arthritis (JIA). Blood concentrations achieved with bDMARDs vary greatly between individual pts. It is not known if higher abatacept (ABA) exposure is linked to higher infection risk in paediatric populations. Objectives To assess the relationship between the incidence of infection and SC (50–125 mg weekly) and IV (10 mg/kg monthly) ABA exposure in pts with p...
Source
Background JIA is the most common chronic inflammatory rheumatic disease of childhood. TNF inhibitors are used for long-term control of pJIA disease. Objectives To evaluate the 7 year (y) safety of Adalimumab treatment with or without methotrexate (ADA±MTX) when used in current clinical practice for treatment of patients (pts) with active pJIA. Methods This is a 7 y interim analysis of an ongoing, multicenter, non-interventional, observational registry of pts with pJIA with up to10 y safety foll...
2 CitationsSource
Background In patients (pts) with polyarticular-course juvenile idiopathic arthritis (pJIA), SC abatacept (ABA) 125 mg weekly has a similar pharmacokinetic profile, therapeutically equivalent efficacy and comparable safety to IV ABA 10 mg/kg every 4 weeks. 1 Although some data on paediatric pt-reported outcomes (PRO) have been published for IV ABA, 2 PRO data following treatment with SC ABA have not. Objectives This analysis examined the effect of SC ABA treatment on PROs (activities of daily li...
1 CitationsSource
#1F De BenedettiH-Index: 20
#2N RupertoH-Index: 7
Last. Hermine I. BrunnerH-Index: 57
view all 18 authors...
Background Efficacy and safety of intravenous (IV) tocilizumab (TCZ) have been shown in patients (pts) with pcJIA.1 Objectives Determine appropriate dosing regimens of SC TCZ in pcJIA. Methods Pts were aged 1–17 y with pcJIA, inadequate response/intolerance to MTX and TCZ-naive or receiving TCZ IV with adequate disease control. TCZ SC was administered open label by body weight (BW)–based dosing modeled on IV dosing in pcJIA and SC dosing in adult rheumatoid arthritis: pcJIA pts Results 52 pts we...
1 CitationsSource